title: [Adjuvant hormone therapy for prostate cancer after local treatment in the context of evidence based medicine].
abstract: At present, prostate cancer is the most frequent malignant disease in German men. The aims of adjuvant hormone treatment are to increase progression free survival and improve cure rate. Risk factors for progression are a Gleason score > or =8, large tumor volumes, a high preoperative PSA (>15-29 ng/ml), penetration of the capsule, positive margins and lymph node metastasis. The type of hormone therapy (LHRH-nnalogues, non-steroidal anti-androgens, surgical castration) should be discussed with the patient. Bicalutamide seems to be an alternative for younger patients due to the lack of side effects of testosterone suppression.
authors.affiliation: Urologische Klinik Bad Mergentheim, Bad Mergentheim, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Heine
authors.forename: J M
authors.initials: JM
authors.lastname: Wolff
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D019317:Evidence-Based Medicine; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D016032:Randomized Controlled Trials as Topic
chemical_list: D018931:Antineoplastic Agents, Hormonal